← Cardiac procedures & devices × cardiovascular events

SynthesisDeutsches Arzteblatt international2016

Ezetimibe-Statin Combination Therapy.

Barbara Nußbaumer et al.PubMed ↗Full text ↗Publisher ↗

  • Ezetimibe-statin combination therapyno clear effectNo clear effect on serious undesired events.No ranges given.

What the trial testedas reported · 461 people · 2016

Range includes no effect

No clear effect on cardiovascular events

0.9×0× to 89×

33 in 100 instead of 35

Bigger than 1 in 10 for cardiovascular events

As reported

HR 0.94, 95% CI 0.00–89.0

Range includes no effect

No clear effect on serious undesired events

+9%−23% to +55%

ezetimibe-statin combination therapy vs statin monotherapy

Bigger than 3 in 10 for adverse events & safety

As reported

RR 1.09, 95% CI 0.77–1.55

+1 more in the walkthrough ↓

Who was studied, and how

461people with cardiovascular disease, in this paper

The trial randomly assignedassigned by chance

ezetimibe-statin combination therapy
statin monotherapy

Reported higher cardiovascular event, no range given+50.0

No clear effect on serious undesired events+9%

randomised

the abstract, start to end

… years (number needed to treat [NNT]: 50 over 7 years).

… and nonfatal stroke (hazard ratio [HR] 0.94, 95% confidence interval [0,89; …

… taking a statin alone (relative risk 1.09 [0.77; 1.55]).

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Cardiovascular eventezetimibe-statin combination therapy vs statin monotherapy
NNT 50
Cardiovascular events
HR 0.940.00–89.0
Serious undesired eventsezetimibe-statin combination therapy vs statin monotherapy
RR 1.090.77–1.55
StatinsOther lipid agentsCardiac procedures & devicesCardiovascular eventsAdverse events & safety
1 / 4

17 papers cite it

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 27412989